ARS signed an extended full-service support contract with a European pharmaceutical company to conduct a randomized, double blind, placebo-controlled Phase III study of efficacy, safety and tolerability in patients with degenerative brain diseases. As a result of expert review of the protocol, ARS CRO intends to enroll 110 elderly patients (instead of 80 initially planned by the Sponsor) at three sites in Russia. The clinical trial is for two years. On finishing a clinical part, ARS will provide marketing authorization of the product in the country.